Blood Culture Tests Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global blood culture tests market, valued at US$4.5 billion in 2021, is forecasted to grow at a robust CAGR of 8.0%, reaching US$5.2 billion in 2023 and an impressive US$7.6 billion by 2028. Growth in this market is majorly driven by the factors such as the growing incidence of sepsis cases and high cost treatment, rising geriatric population, high incidence of bloodstream infections, growing demand for rapid diagnostic techniques and high prevalence of infectious diseases. On the other hand, high cost of automated instruments and lack of trained laboratory technicians are expected to restrain the market growth to some extent in the future.

Blood Culture Tests Market - Global Forecast to 2028

To know about the assumptions considered for the study, Request for Free Sample Report

Blood Culture Tests Market Opportunities

Blood Culture Tests Market Dynamics

Drivers: Growing incidence of sepsis cases and high cost of treatment

Sepsis is a medical condition in which the body is prone to severe inflammatory responses to fungal and bacterial infections. Patients with chronic illness, implanted devices, and those with suppressed immune systems are more prone to growing sepsis.

Sepsis is considered a significant global socioeconomic burden as sepsis and septic shock are associated with a high morbidity rate (which may result in a prolonged hospital stay and increase the associated healthcare costs) and mortality rate. According to the Centre of Disease Control and Prevention (CDC), every year in the US, sepsis leads to more deaths than opioid overdoses, prostate cancer and breast cancer combined.

Restraints: Lack of trained laboratory technicians

Advancements in the technology in blood culture tests have increased their adoption among hospital and reference laboratories, which are major end users of these tests. Clinical guidelines and clinician education influence how diagnostic tests are incorporated into clinical practices. For providing improved patient care, it becomes necessary to engage a clinician’s expertise to determine the best diagnostic tests and interpret correct laboratory results. As the level of awareness about the latest technological advancements in blood culture tests is low among technicians (especially in emerging economies), the adoption of advanced technologies is restricted to a great extent. This is limiting the use of best diagnostic practices and restraining the greater uptake of technologically advanced products.

Opportunities: Growth opportunities in emerging economies

Growing countries such as China, India, Brazil, South Korea, Turkey, South Africa and Russia are expected to offer significant growth opportunities to market players during the forecast period. The economic boom over the last few years in these countries is expected to boost the growth of the healthcare sector and create growth opportunities for players operating in the blood culture test market.

Such significant spending will result in the adoption of advanced systems, such as automated blood culture systems, among hospital and reference laboratories in these regions. This, in turn, is expected to provide potential growth opportunities for players operating in the market in the future.

Challenges: Market Cannibalization for conventional products

In recent years, several technologically advanced products that provide enhanced solutions for the detection of microorganisms present in the bloodstream have been launched in the market. These advanced products are expected to cannibalize the market for conventional products, such as microscopes and polystainers, thereby affecting the growth of conventional blood culture testing products. To maintain a competitive position in the market, players need to diversify their product portfolio by adopting new technologies. This will be a challenging task for the market players who have an established portfolio of conventional products to discard all their available products.

Blood Culture Tests Market Ecosystem Analysis

The conventional/manual blood culture segment has accounted for the largest share of the blood culture tests market during the forecast period.

Based on method, the market is segmented into conventional/manual blood culture and automated blood culture methods. The conventional/manual blood culture methods segment accounted for the largest share of of the global blood culture tests market. The large share of this segment can be attributed to ease of using conventional systems. Also, conventional systems do not require the purchase of expensive instruments.

The consumables segment has accounted for the largest share of the blood culture tests market during the forecast period.

Based on products, the market is primarily divided into consumables, instruments, and software and services. Due to the repeated purchase of media for the detection of bacteria, fungi, and yeast, the consumables segment captures the largest share and is also the fastest growing.

The culture-based technologies segment has accounted for the largest share of the blood culture tests market during the forecast period.

Based on technology, culture-based technologies, molecular technologies, and proteomics make up the major segments of this market. The molecular technologies segment accounted for the high growth in the global blood culture tests market. This can be attributed to the increasing incidence of sepsis, which demands rapid diagnostic techniques for detecting the presence of bacteria, fungi, and mycobacteria from blood samples.

The bacteremia segment has accounted for the largest share of the blood culture tests market during the forecast period.

Based on application, the market is divided into bacteremia, fungemia, and mycobacterial detection. Bacteremia segment is accounted for the largest as well as the highest growing share in the blood culture tests market. This is due to the increasing number of bloodstream infections and the growing number of sepsis cases worldwide.

The hospital laboratories segment has accounted for the largest share of the blood culture tests market during the forecast period.

Based on end users, the market is bifurcated into hospital laboratories, reference laboratories, academic research laboratories, and other laboratories (includes pathology laboratories, bacteriological laboratories, physician office laboratories (POLs), and independent research laboratories). The reference laboratories segment is expected to grow at the highest rate in this market. The high growth of this segment is due to the increasing outsourcing of blood culture tests by hospitals to reference laboratories.

North America accounted for the largest share of the blood culture tests market.

The market is segmented into four major regions–North America, Europe, the Asia Pacific (APAC), and the Middle East & Africa. North America has accounted for the largest market share. Factors such as the increasing incidence of bloodstream infections, high prevalence of infectious diseases, rapidly rising geriatric population, the significant presence of blood culture test providers, and growing product approvals are driving the growth of the market in North America.

Blood Culture Tests Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in blood culture tests market are Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio (England), Anaerobe Systems, Inc. (US), Himedia Laboratories Pvt. Ltd. (India), Autobio Diagnostics Co., Ltd. (China), Axiom Laboratories (India), Iridica (US), Biosystems, Inc (US), BINDER GmBH (Germany), Terumo Corporation (Japan), Becton, Dickinson and Company (US), BioMérieux (France), Thermo Fisher Scientific Inc. (US), Danaher (US), Luminex Corporation (US), Bruker (US), Roche Diagnostics  (Switzerland), Mikroscan Technologies, Inc. (US), Labotronics Ltd. (UK), Hardy Diagnostics (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Carl Zeiss AG (Germany) and Nikon Corporation (Japan).

Blood Culture Tests Market Report Scope

This research report categorizes the blood culture tests market to forecast revenue and analyze trends in each of the following submarkets:

By Method

• Conventional/Manual Methods
• Automated Methods

By Product

• Consumables
  • Blood Culture Media
    • Aerobic Blood Culture Media
    • Pediatric Aerobic Blood Culture Media
    • Anaerobic Blood Culture Media
    • Mycobacterial Blood Culture Media
    • Fungi/Yeast Blood Culture Media
  • Assay Kits & Reagents
  • Blood Culture Accessories
• Instruments
  • Automated Blood Culture Systems
  • Supporting Laboratory Equipment
    • Incubators
    • Colony Counters
    • Microscopes
    • Gram Stainers
• Software and Services

By Technology

• Culture-Based Technology
• Molecular Technologies
  • Microarrays
  • PCR (Polymerase Chain Reaction)
  • PNA-FiSH (Peptide Nucleic Acid – Fluroscent in Situ Hybridization)
• Proteomics Technology

By Application

• Bacteremia
• Fungemia
• Mycobacterial Detection

By End User

• Hospital Laboratories
• Reference Laboratories
• Academic Research Laboratories
• Other Laboratories

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Recent Developments of Blood Culture Tests Market

• In 2023, BioMérieux, announced that it has submitted a 510(k) premarket notification to the US Food and Drug Administration (FDA) for the VITEK REVEAL, formerly known as SPECIFIC REVEALRapid AST System. This rapid, modular, antimicrobial-susceptibility test platform that can deliver actionable results for Gram-negative bacteria directly from positive blood cultures in an average of five and a half hours1 enabling same-day treatment decision-making for patients suffering from bacteremia sepsis.
• In 2023, Bruker introduces fast next-generation MALDI Biotyper IVD Software. The MBT Compass HT IVD software provides a high sample throughput for microbial identification with time-to-result of ~5 minutes for 96 sample spots. Because of a fast sample target exchange, the MBT system can now analyze up to 600 samples per hour, while covering over 4,600 species in the reference library.
• In 2022, BioMérieux, a world leader in the field of in vitro diagnostics, has entered into an agreement to acquire Specific Diagnostics, a privately held US based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures. BioMérieux has held a minority stake in Specific Diagnostics since 2019, and the two companies had signed a co-distribution agreement covering the European market in 2021. With the addition of SPECIFIC REVEAL Rapid AST, the unique and comprehensive BioMérieux Sepsis Solution allows same-day AST results for Gram-negative bacteria to enable more targeted therapy and improve patient outcomes.
• In 2022, Beckman Coulter, partnered with Germany-based company Smart4Diagnostics to close the preanalytical data gap between blood collection and laboratory analysis due to errors that take place before the sample arrives in the laboratory, such as sample collection, patient identification, sample handling, sample transportation, sample loss, etc.
• In 2020, Becton, Dickinson and Company obtained the CE mark approval for the BD Vacutainer UltraTouch Push Button Blood Collection Set (BCS) with Preattached Holder. The one-handed safety activation of the push button allows clinicians to activate the safety mechanism while still attending to the patient and venipuncture site.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst